Systems biology and the host response to viral infection

Nature Biotechnology

Volumn 25, Issue 12, 2007, Pages 1383-1389

  Tan, Seng Lai ^a   Ganji, Gopinath ^b   Paeper, Bryan ^c   Proll, Sean ^c   Katze, Michael G ^c  

^a AMGEN INC   (United States)

^b Eli Lilly Singapore Pte Ltd   (Singapore)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 BENZYL 8 HYDROXY 2 (2 METHOXYETHOXY)ADENINE; CELSENTRI; CPG 10101; CYCLIN DEPENDENT KINASE INHIBITOR; IMIQUIMOD; ISATORIBINE; MARAVIROC; NITAZOXANIDE; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; SELZENTRY; SM 360320; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BIOINFORMATICS; BIOLOGY; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; GENETIC VARIABILITY; GENOMICS; HEALTH PROGRAM; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MEDICAL TECHNOLOGY; MOLECULAR BIOLOGY; NONHUMAN; NOTE; PATHOGENESIS; PHARMACOGENOMICS; PRIORITY JOURNAL; PUBLIC HEALTH; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMS BIOLOGY; TREATMENT OUTCOME; VIROLOGY; VIRUS CELL INTERACTION; VIRUS INFECTION; WART VIRUS;

DRUG DELIVERY SYSTEMS; GENE TARGETING; GENOMICS; HUMANS; IMMUNITY, NATURAL; SYSTEMS BIOLOGY; VIRUS DISEASES;

EID: 36849029833     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt1207-1383     Document Type: Note

References (59)

1. Noble, D. The Music of Life: Biology Beyond the Genome (Oxford University Press, New York, 2006).
2. Salerno, D. et al. Direct inhibition of CDK9 blocks HIV-1 replication without preventing T-cell activation in primary human peripheral blood lymphocytes. Gene 405, 65-78 (2007).
3. Schang, L.M. First demonstration of the effectiveness of inhibitors of cellular protein kinases in antiviral therapy. Expert Rev. Anti Infect. Ther. 4, 953-956 (2006).
4. de Angelis, D.S., Freire, W.S., Pannuti, C.S., Succi, R.C. & Machado, D.M. CCR5 genotypes and progression to HIV disease in perinatally infected children. Braz. J. Infect. Dis. 11, 196-198 (2007).
5. Wheeler, J., McHale, M., Jackson, V. & Penny, M. Assessing theoretical risk and benefit suggested by genetic association studies of CCR5: experience in a drug development programme for maraviroc. Antivir. Ther. 12, 233-245 (2007).
6. Tan, S.L., He, Y., Huang, Y. & Gale, M. Jr. Strategies for hepatitis C therapeutic intervention: now and next. Curr. Opin. Pharmacol. 4, 465-470 (2004).
7. Horsmans, Y. et al. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology 42, 724-731 (2005).
8. Lee, J. et al. Activation of anti-hepatitis C virus responses via Toll-like receptor 7. Proc. Natl. Acad. Sci. USA 103, 1828-1833 (2006).
9. Vanwolleghem, T. et al. Ultra-rapid cardiotoxicity of the hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse. Gastroenterology 133, 1144-1155 (2007).
10. ViroPharma Inc. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796 (press release) (ViroPharma Inc., Exton, Pennsylvania, USA, 2007).
11. Davidov, E., Holland, J., Marple, E. & Naylor, S. Advancing drug discovery through systems biology. Drug Discov. Today 8, 175-183 (2003).
12. Butcher, E.C., Berg, E.L. & Kunkel, E.J. Systems biology in drug discovery. Nat. Biotechnol. 22, 1253-1259 (2004).
13. Gibbs, R.A. et al. Evolutionary and biomedical insights from the rhesus macaque genome. Science 316, 222-234 (2007).
14. Wallace, J.C. et al. High-density rhesus macaque oligonucleotide microarray design using early-stage rhesus genome sequence information and human genome annotations. BMC Genomics 8, 28 (2007).
15. Tumpey, T.M. et al. Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science 310, 77-80 (2005).
16. Kobasa, D. et al. Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature 445, 319-323 (2007).
17. Walters, K.A. et al. Application of functional genomics to the chimeric mouse model of HCV infection: optimization of microarray protocols and genomics analysis. Virol. J. 3, 37-44 (2006).
18. Kash, J.C. et al. Global suppression of the host antiviral response by Ebola- and Marburgviruses: increased antagonism of the type 1 interferon response is associated with enhanced virulence. J. Virol. 80, 3009-3020 (2006).
19. Fredericksen, B.L., Smith, M., Katze, M.G., Shi, P.Y. & Gale, M. Jr. The host response to West Nile Virus infection limits viral spread through the activation of the interferon regulatory factor 3 pathway. J. Virol. 78, 7737-7747 (2004).
20. Baas, T., Taubenberger, J., Chong, P.Y., Chui, P. & Katze, M.G. SARS-CoV virus-host interactions and comparative etiologies of acute respiratory distress syndrome as determined by transcriptional and cytokine profiling of formalin-fixed paraffin-embedded tissues. J. Interferon Cytokine Res. 26, 309-317 (2006).
21. Pasieka, T.J. et al. Functional genomics analysis of herpes simplex virus type 1 counteraction of the host innate response. J. Virol. 80, 7600-7612 (2006).
22. Li, Y., Chan, E.Y. & Katze, M.G. Functional genomics analyses of differential macaque peripheral blood mononuclear cell infections by human immunodeficiency virus-1 and simian immunodeficiency virus. Virology 366, 137-149 (2007).
23. Wallace, J.C., Korth, M.J., Diamond, D.L., Proll, S.C. & Katze, M.G. Virology in the 21st century: finding function with functional genomics. Future Virol. 1, 47-53 (2006).
24. Diamond, D.L. et al. Proteomic profiling of human liver biopsies: hepatitis C virus-induced fibrosis and mitochondrial dysfunction. Hepatology 46, 649-657 (2007).
25. Bandyopadhyay, S., Kelley, R. & Ideker, T. Discovering regulated networks during HIV-1 latency and reactivation. Pac. Symp. Biocomput. 11, 354-366 (2006).
26. Uetz, P. et al. Herpesviral protein networks and their interaction with the human proteome. Science 311, 239-242 (2006).
27. Chan, L.Y., Kosuri, S. & Endy, D. Refactoring bacteriophage T7. Mol. Syst. Biol. 1, 2005.0018 (2005).
28. Bartee, E., McCormack, A. & Fruh, K. Quantitative membrane proteomics reveals new cellular targets of viral immune modulators. PLoS Pathog. 2, e107 (2006).
29. Bentwich, I. Bioinformatically detectable group of novel HIV regulatory genes and uses thereof. US Patent 7,217,807 (2007).
30. Burnside, J. et al. Marek's disease virus encodes MicroRNAs that map to meq and the latency-associated transcript. J. Virol. 80, 8778-8786 (2006).
31. Cai, X. et al. Kaposi's sarcoma-associated herpesvirus expresses an array of viral microRNAs in latently infected cells. Proc. Natl. Acad. Sci. USA 102, 5570-5575 (2005).
32. Cui, C. et al. Prediction and identification of herpes simplex virus 1-encoded microRNAs. J. Virol. 80, 5499-5508 (2006).
33. Grey, F. et al. Identification and characterization of human cytomegalovirus-encoded microRNAs. J. Virol. 79, 12095-12099 (2005).
34. Pfeffer, S. Identification of virally encoded microRNAs. Methods Enzymol. 427, 51-63 (2007).
35. Sullivan, C.S., Grundhoff, A.T., Tevethia, S., Pipas, J.M. & Ganem, D. SV40-encoded microRNAs regulate viral gene expression and reduce susceptibility to cytotoxic T cells. Nature 435, 682-686 (2005).
36. Grundhoff, A., Sullivan, C.S. & Ganem, D. A combined computational and microarray-based approach identifies novel microRNAs encoded by human gamma-herpesviruses. RNA 12, 733-750 (2006).
37. + cell proteome: dysregulated cell cycle progression and nuclear transport coincide with robust virus production. J. Virol. 81, 7571-7583 (2007).
38. Zhu, H., Cong, J.P., Mamtora, G., Gingeras, T. & Shenk, T. Cellular gene expression altered by human cytomegalovirus: global monitoring with oligonucleotide arrays. Proc. Natl. Acad. Sci. USA 95, 14470-14475 (1998).
39. Moses, A.V. et al. A functional genomics approach to Kaposi's sarcoma. Ann. NY Acad. Sci. 975, 180-191 (2002).
40. + T cells in viremic versus aviremic HIV-infected individuals. Proc. Natl. Acad. Sci. USA 100, 1908-1913 (2003).
41. Sakamoto, H. et al. Host sphingolipid biosynthesis as a target for hepatitis C virus therapy. Nat. Chem. Biol. 1, 333-337 (2005).
42. Pelkmans, L. et al. Genome-wide analysis of human kinases in clathrin- and caveolae/raft-mediated endocytosis. Nature 436, 78-86 (2005).
43. Fellay, J. et al. A whole-genome association study of major determinants for host control of HIV-1. Science 317, 944-947 (2007).
44. Foulkes, A.S. et al. Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy. PLoS Med. 3, e52 (2006).
45. Haas, D.W. Human genetic variability and HIV treatment response. Curr. HIV/AIDS Rep. 3, 53-58 (2006).
46. Dahri, K. & Ensom, M.H. Efavirenz and nevirapine in HIV-1 infection: is there a role for clinical pharmacokinetic monitoring? Clin. Pharmacokinet. 46, 109-132 (2007).
47. Wright, M., Grieve, R., Roberts, J., Main, J., & Thomas, H.C. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol. Assess. 10, 1-113, iii (2006).
48. Xie, Y. et al. Predictive factors for sustained response to interferon treatment in patients with chronic hepatitis C: a randomized, open, and multi-center controlled trial. Hepatobiliary Pancreat. Dis. Int. 4, 213-219 (2005).
49. Angulo, M. & Carvajal-Rodriguez, A. Evidence of recombination within human alpha-papillomavirus. Virol. J. 4, 33-40 (2007).
50. Ding, X.R., Yang, J., Sun, D.C., Lou, S.K. & Wang, S.Q. Whole genome expression profiling of hepatitis B virus-transfected cell line reveals the potential targets of anti-HBV drugs. Pharmacogenomics. J. published online (15 May 2007). doi:10.1038/sj.tpj.6500459
51. Damm, E.M. & Pelkmans, L. Systems biology of virus entry in mammalian cells. Cell. Microbiol. 8, 1219-1227 (2006).
52. Silver, P.A. & Way, J.C. Molecular systems biology in drug development. Clin. Pharmacol. Ther. 82, 586-590 (2007).
53. Giuliano, K.A., Johnston, P.A., Gough, A. & Taylor, D.L. Systems cell biology based on high-content screening. Methods Enzymol. 414, 601-619 (2006).
54. Piwnica-Worms, D., Schuster, D.P. & Garbow, J.R. Molecular imaging of host-pathogen interactions in intact small animals. Cell. Microbiol. 6, 319-331 (2004).
55. He, M.L. et al. Inhibition of SARS-associated coronavirus infection and replication by RNA interference. JAMA 290, 2665-2666 (2003).
56. Neuman de Vegvar, H.E. et al. Microarray profiling of antibody responses against simian-human immunodeficiency virus: postchallenge convergence of reactivities independent of host histocompatibility type and vaccine regimen. J. Virol. 77, 11125-11138 (2003).
57. Aderem, A. Systems biology: its practice and challenges. Cell 121, 511-513 (2005).
58. Holmes, E.C. Viral evolution in the genomic age. PLoS Biol. 5, e278 (2007).
59. Braga-Neto, U.M. & Marques, E.T. Jr. From functional genomics to functional immunomics: new challenges, old problems, big rewards. PLoS Comput. Biol 2, e81 (2006).